Unresectable Thymic Carcinoma clinical trials at UC Cancer
1 research study open to eligible people
Experimental Carboplatin & Paclitaxel With or Without Ramucirumab For Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma
open to eligible people ages 18 years and up
This randomized phase II trial studies how well carboplatin and paclitaxel with or without ramucirumab work in treating patients with thymic cancer that has spread to other places in the body, has come back, or cannot be removed by surgery. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as ramucirumab, may interfere with the ability of tumor cells to grow and spread. It is not yet known if giving carboplatin and paclitaxel with or without ramucirumab will work better in treating patients with thymic cancer.
at UC Davis
Our lead scientists for Unresectable Thymic Carcinoma research studies include Jonathan W. Riess.